Resources

Piloted in 2021, the Digital Health Applied Leadership program (DHALP) is an executive training program that enhances participants’ capacity to successfully lead and execute digital health programs. With support from the United States Agency for International Development (USAID), the US President’s Emergency Plan for AIDS Relief (PEPFAR), BACKUP Health, and partners like the World Health Organization (WHO), the World Bank, and TechChange, the pilot program trained 42 leaders from four countries in planning digital health systems, management, and leadership. In an evaluation, participants indicated the relevance and practicality of training, increase in knowledge, confidence, application of concepts, and institutionalization of learning within the ministry. The program is currently (2025) being implemented in Burkina Faso, Rwanda, and Zambia with 60 midlevel digital health leaders.

To achieve sustainability in digital health, we need a shared understanding of market forces and their influence on the digital health sector.Market forces have a role in determining:Which digital health tools get introduced, adopted, and scaled.The underlying costs of digital tools.The long-term opportunities for financing the digital transformation of health systems.Through a series of analyses, PATH Digital Square, Vital Wave, and a consortium of partners whose publications are featured here have identified current challenges to sustainability, outlined cost drivers for digital health software, and developed recommendations, tools, and models that can lead to a more sustainable digital health marketplace.

This slide provides a snapshot of the Group B Streptococcus (GBS) vaccine technology landscape, in the effort to track the development of GBS vaccine candidates and provide a summary of the various vaccine approaches being worked on around the world.This snapshot pairs with the GBS Vaccine Clinical Trial Tracker, which provides publicly available information on clinical trials of GBS vaccine candidates intended for disease prevention.To share any updates or corrections to the snapshot, please contact gbssnapshot@path.org.

This spreadsheet provides publicly available information on clinical trials of Group B Streptococcus (GBS) candidate vaccines intended for disease prevention.Sources of information for these trials include clinicaltrials.gov, who.int/clinical-trials-registry-platform, clinicaltrialsregister.eu, chictr.org.cn, and anzctr.org.au.Some information is also obtained through contact with investigators, sponsors, and funders of vaccine clinical trials. This spreadsheet pairs with the GBS Vaccine Snapshot, which provides a summary of the GBS vaccine candidates in development worldwide.To share any updates or corrections to the tracker, please contact gbssnapshot@path.org.

To support the development and introduction of more sensitive rapid diagnostic tests (RDTs) for malaria, PATH and the Institut Pasteur de Dakar partnered to evaluate the performance of three novel LDH-based RDTs developed by Rapigen (Republic of Korea). This study evaluated the clinical performance and usability of three of Rapigen’s BIOCREDIT RDTs among a febrile population in Kédougou, Senegal, comparing them to current tests (the standard HRP2-based RDT and microscopy) and against PCR and quantitative antigen reference assays. The following brief summarizes key results from this evaluation.